Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00392288
Status:
COMPLETED
Last Update Posted:
2017-02-01
First Post:
2006-10-24
Brief Title:
Efficacy and Safety of Ciclesonide CIC Administered Twice Daily in Pediatric Patients With Asthma
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multicenter Multi-national Randomized Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler MDI at 80 μg BID or 40 μg BID for 12 Weeks in Patients Aged 4 to 12 Years With Persistent Asthma
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective To demonstrate the efficacy of ciclesonide compared to placebo at 80 μg twice daily BID or 40 μg BID for 12 weeks in patients with persistent asthma
Secondary objective To assess the safety and tolerability of ciclesonide
Secondary objective To assess the safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| XRP1526 | None | None | None |